Last Updated : April 27, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Zinbryta | Daclizumab beta | Multiple Sclerosis, relapsing-remitting | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zolgensma | onasemnogene abeparvovec | Spinal muscular atrophy (SMA), pediatrics | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zolinza | vorinostat | Cutaneous T-cell lymphoma | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Zoryve | roflumilast | Plaque psoriasis | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zydelig | Idelalisib | Chronic lymphocytic leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zydelig | Idelalisib | Follicular Lymphoma | Do not reimburse | Complete | ||
| Zykadia | Ceritinib | Metastatic Non-Small Cell Lung Cancer | Do not reimburse | Complete | ||
| Zykadia (Resubmission) | Ceritinib | metastatic non-small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Zytiga | Abiraterone | Withdrawn | ||||
| Zytiga | Abiraterone acetate | Metastatic Castration Resistant Prostate Cancer | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : April 27, 2024